Home / news / Vertex Pharma to seek approval of new cystic fibrosis drug – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Vertex Pharma to seek approval of new cystic fibrosis drug – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

collected by :Molly Tony

Vertex Pharmaceuticals (NASDAQ:VRTX) +6.3% AH after saying it would apply for regulatory approval in the U.S. and European Union for an experimental cystic fibrosis drug after the treatment significantly improved lung function in late-stage trials.
If approved, the new drug would present patients with an alternative to the company’s drug Orkambi, which can cause chest tightness and other side effects that have led to disappointing sales.
The drug is intended to treat patients who have one or two copies of a genetic mutation that is the most common cause of cystic fibrosis, a progressive lung disease that affects ~30K people in the U.S.

as mentioned in

Vertex Pharmaceuticals Incorporated (VRTX) Upgraded to Buy at Zacks Investment Research

Vertex Pharmaceuticals Company ProfileVertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases.
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com’s FREE daily email newsletter.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was upgraded by Zacks Investment Research from a “strong sell” rating to a “buy” rating in a research note issued on Tuesday.
Also, Director Joshua S. Boger sold 6,500 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, December 29th.
In other news, Director Joshua S. Boger sold 8,000 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, January 11th.

Stocks to Watch: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Innocoll Holdings plc (NASDAQ:INNL)

as mentioned in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is currently trading with the volume of 9.21 Million.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) topped its 52-week high price of $111.88 on Aug 9, 2016 and 52-Week Low Price of $71.46 on Dec 22, 2016.
Innocoll Holdings plc (NASDAQ:INNL) topped its 52-week high price of $12.94 on Jun 3, 2016 and 52-Week Low Price of $0.53 on Feb 1, 2017.
Vertex Pharmaceuticals Incorporated has 1 year price target of $100.25.
Innocoll Holdings plc (NASDAQ:INNL)Innocoll Holdings plc (NASDAQ:INNL) is currently trading with the volume of 8.41 Million.

read more
visit us
Markets

Check Also

cheap stocks

Cheap stocks and its trading in financial markets

Cheap stocks, also known as Cent stocks, are ordinary shares of small public companies traded …